Valuation : Clarity Pharmaceuticals Ltd

Market Cap 936M 672M 579M 543M 496M 933M 64.21B 6.44B 2.51B 32.41B 2.52B 2.47B 107B P/E 2027 *
-8.62x
P/E 2028 * -10.8x
Enterprise Value 872M 626M 539M 506M 462M 870M 59.81B 6B 2.34B 30.19B 2.35B 2.3B 100B EV / Sales 2027 *
935x
EV / Sales 2028 * 13.8x
Free-Float
79.07%
Yield 2027 *
-
Yield 2028 * -
1 day+7.26%
1 week+1.21%
Current month+5.91%
1 month+20.10%
3 months+0.80%
6 months-30.47%
Current year-25.74%
1 week 2.28
Extreme 2.28
2.55
1 month 2.16
Extreme 2.16
2.96
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.98
Extreme 0.975
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 10/10/2024
Chief Executive Officer - 31/12/2009
Director of Finance/CFO - 03/04/2022
Director TitleAgeSince
Chairman - 31/10/2013
Director/Board Member - 30/09/2010
Director/Board Member 72 28/03/2016
Date Insider Type Main position Quantity % Market Cap.
22/04/26 Sell

Chief Executive Officer

360,896 0.0969%
28/11/25 Free

Chief Operating Officer

199,909 0.0537%
28/11/25 Free

Chief Operating Officer

287,530 0.0773%
Change 5-day change 1-year change 3-year change Capi.($)
+7.26%+1.21%-15.77%+128.18% 672M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.09%-1.61%+50.42%+185.19% 28.26B
Weighted average by Cap. -1.91%-1.50%+53.56%+151.45%

Financials

2027 *2028 *
Net sales 933K 670K 577K 541K 494K 930K 64M 6.42M 2.5M 32.31M 2.51M 2.46M 107M 61.76M 44.31M 38.18M 35.8M 32.68M 61.56M 4.23B 425M 166M 2.14B 166M 163M 7.09B
Net income -120M -86.11M -74.2M -69.57M -63.51M -120M -8.23B -825M -322M -4.15B -323M -316M -13.78B -88.68M -63.63M -54.83M -51.41M -46.93M -88.4M -6.08B -610M -238M -3.07B -239M -234M -10.18B
Net Debt -64.16M -46.03M -39.67M -37.19M -33.95M -63.96M -4.4B -441M -172M -2.22B -173M -169M -7.36B -87.22M -62.58M -53.92M -50.56M -46.15M -86.94M -5.98B -600M -234M -3.02B -235M -230M -10.01B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
100
Date Price Change Volume
28/08/26 A$2.510 +7.26% 2,028,202
27/08/26 A$2.340 -6.40% 2,385,093
26/08/26 A$2.500 +0.81% 1,170,950
25/08/26 A$2.480 +3.77% 1,130,747
24/08/26 A$2.390 -3.63% 2,005,157
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.510AUD
Average target price
7.202AUD
Spread / Average Target
+186.95%

Quarterly revenue - Rate of surprise